Cargando…

Rasagiline – a novel MAO B inhibitor in Parkinson’s disease therapy

Parkinson’s disease (PD) is a progressive neurodegenerative, dopamine deficiency disorder. The main therapeutic strategies for PD treatment relies on dopamine precursors (levodopa), inhibition of dopamine metabolism (monoamine oxidase [MAO] B and catechol-O-methyl transferase inhibitors), and dopami...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lecht, Shimon, Haroutiunian, Simon, Hoffman, Amnon, Lazarovici, Philip
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2007
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2386362/ https://www.ncbi.nlm.nih.gov/pubmed/18488080

Ejemplares similares

Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson’s Disease with Neuroprotective Potential
por: Finberg, John P.M.
Publicado: (2010)

Adjunctive therapy in Parkinson’s disease: the role of rasagiline
por: Gaines, Kathryn D, et al.
Publicado: (2012)

Rasagiline in treatment of Parkinson’s disease
por: Nayak, Lakshmi, et al.
Publicado: (2008)

Human Umbilical Cord Blood Stem Cells: Rational for Use as a Neuroprotectant in Ischemic Brain Disease
por: Arien-Zakay, Hadar, et al.
Publicado: (2010)

MAO-inhibitors in Parkinson's Disease
por: Riederer, Peter, et al.
Publicado: (2011)

The role of rasagiline in the treatment of Parkinson’s disease
por: Leegwater-Kim, Julie, et al.
Publicado: (2010)

Rasagiline Withdrawal Syndrome in Parkinson’s Disease
por: Solla, Paolo, et al.
Publicado: (2022)

From a Parkinson's disease expert: Rasagiline and the Future of Therapy
por: Lakhan, Shaheen E
Publicado: (2007)

A critical appraisal of MAO-B inhibitors in the treatment of Parkinson’s disease
por: Jost, Wolfgang H.
Publicado: (2022)

Role of rasagiline in treating Parkinson’s disease: Effect on disease progression
por: Malaty, Irene A, et al.
Publicado: (2009)

Comparison of Selegiline and Rasagiline Therapies in Parkinson Disease: A Real-life Study
por: Peretz, Chava, et al.
Publicado: (2016)

Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson’s disease
por: Teo, Kay Cheong, et al.
Publicado: (2013)

Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology
por: Finberg, John P. M., et al.
Publicado: (2016)

Near Infrared Optical Visualization of Epidermal Growth Factor Receptors Levels in COLO205 Colorectal Cell Line, Orthotopic Tumor in Mice and Human Biopsies
por: Cohen, Gadi, et al.
Publicado: (2013)

Effects of combined MAO-B inhibitors and levodopa vs. monotherapy in Parkinson’s disease
por: Krishna, Rakhee, et al.
Publicado: (2014)

Novel Series of Dual NRF2 Inducers and Selective MAO-B Inhibitors for the Treatment of Parkinson’s Disease
por: Duarte, Pablo, et al.
Publicado: (2022)

Rasagiline and Rapid Symptomatic Motor Effect in Parkinson’s Disease: Review of Literature
por: Pistacchi, Michele, et al.
Publicado: (2013)

Reversible Small Molecule Inhibitors of MAO A and MAO B with Anilide Motifs
por: Hagenow, Jens, et al.
Publicado: (2020)

Rasagiline Ameliorates Olfactory Deficits in an Alpha-Synuclein Mouse Model of Parkinson's Disease
por: Petit, Géraldine H., et al.
Publicado: (2013)

Rasagiline for sleep disorders in patients with Parkinson’s disease: a prospective observational study
por: Schettino, Carla, et al.
Publicado: (2016)

Rasagiline, sleep quality and well-being in Parkinson’s disease: a pilot study
por: Mutti, Carlotta, et al.
Publicado: (2022)

No synergism between bis(propyl)-cognitin and rasagiline on protecting dopaminergic neurons in Parkinson's disease mice
por: Zheng, Cheng-you, et al.
Publicado: (2016)

Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson’s Disease: A Post Hoc Analysis
por: Giladi, Nir, et al.
Publicado: (2016)

Rasagiline does not exacerbate autonomic blood pressure dysregulation in early or mild Parkinson’s disease
por: Oka, Hisayoshi, et al.
Publicado: (2021)

Rasagiline as Adjunct to Levodopa for Treatment of Parkinson's Disease: A Systematic Review and Meta-Analysis
por: Kano, Osamu, et al.
Publicado: (2022)

Curcumin modulation of L-dopa and rasagiline-induced neuroprotection in rotenone model of Parkinson’s disease
por: El-Shamarka, Marwa El-Sayed, et al.
Publicado: (2023)

Structure-Based Design of Novel MAO-B Inhibitors: A Review
por: Mateev, Emilio, et al.
Publicado: (2023)

KDS2010, a Newly Developed Reversible MAO-B Inhibitor, as an Effective Therapeutic Candidate for Parkinson’s Disease
por: Nam, Min-Ho, et al.
Publicado: (2021)

Effects of MAO-B inhibitors on non-motor symptoms and quality of life in Parkinson’s disease: A systematic review
por: Tsuboi, Takashi, et al.
Publicado: (2022)

Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations
por: Regensburger, Martin, et al.
Publicado: (2023)

Discovery of novel 2-(4-(benzyloxy)-5-(hydroxyl) phenyl) benzothiazole derivatives as multifunctional MAO-B inhibitors for the treatment of Parkinson’s disease
por: Cao, Zhongcheng, et al.
Publicado: (2023)

P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson’s Disease
por: Hauser, Robert A., et al.
Publicado: (2022)

Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson’s disease
por: Hattori, Nobutaka, et al.
Publicado: (2019)

Novel Thiosemicarbazone Derivatives: In Vitro and In Silico Evaluation as Potential MAO-B Inhibitors
por: Osmaniye, Derya, et al.
Publicado: (2021)

Computationally Assisted Lead Optimization of Novel Potent and Selective MAO-B Inhibitors
por: Gogineni, Vedanjali, et al.
Publicado: (2021)

Development of a Novel Class of Pyridazinone Derivatives as Selective MAO-B Inhibitors
por: Alagöz, Mehmet Abdullah, et al.
Publicado: (2022)

Synthesis and Evaluation of Phenylxanthine Derivatives as Potential Dual A2AR Antagonists/MAO-B Inhibitors for Parkinson’s Disease
por: Wang, Xuebao, et al.
Publicado: (2017)

MAO-B Elevation in Mouse Brain Astrocytes Results in Parkinson's Pathology
por: Mallajosyula, Jyothi K., et al.
Publicado: (2008)

Preparation and evaluation of injectable Rasagiline mesylate dual-controlled drug delivery system for the treatment of Parkinson’s disease
por: Jiang, Ying, et al.
Publicado: (2017)

Adjunct rasagiline to treat Parkinson’s disease with motor fluctuations: a randomized, double-blind study in China
por: Zhang, Zhenxin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qnos5i655iph0ql3vgqmeaiiv4